Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Mar;200(3):210-5.
doi: 10.1192/bjp.bp.110.081992. Epub 2011 Oct 7.

Effects of anxiety on the long-term course of depressive disorders

William Coryell  1 , Jess G Fiedorowicz, David Solomon, Andrew C Leon, John P Rice, Martin B Keller
Affiliations

Effects of anxiety on the long-term course of depressive disorders

William Coryell et al. Br J Psychiatry. 2012 Mar.

Abstract

Background: It is well established that the presence of prominent anxiety within depressive episodes portends poorer outcomes. Important questions remain as to which anxiety features are important to outcome and how sustained their prognostic effects are over time.

Aims: To examine the relative prognostic importance of specific anxiety features and to determine whether their effects persist over decades and apply to both unipolar and bipolar conditions.

Method: Participants with unipolar (n = 476) or bipolar (n = 335) depressive disorders were intensively followed for a mean of 16.7 years (s.d. = 8.5).

Results: The number and severity of anxiety symptoms, but not the presence of pre-existing anxiety disorders, showed a robust and continuous relationship to the subsequent time spent in depressive episodes in both unipolar and bipolar depressive disorder. The strength of this relationship changed little over five successive 5-year periods.

Conclusions: The severity of current anxiety symptoms within depressive episodes correlates strongly with the persistence of subsequent depressive symptoms and this relationship is stable over decades.

PubMed Disclaimer

Conflict of interest statement

Declaration of interest

A.C.L. has served on Data Safety Monitoring Boards for AstraZeneca, Dainippon Sumitomo Pharma America, Pfizer, Merck, Neuronetics and Vanda, and served as a consultant to the FDA, NIMH, Avera, Cyberonics, Eli Lilly, Schering Plough and Takeda. M.B.K. has received honoraria from and/or served as a consultant or on advisory boards with: Abbott, CENEREX, Cephalon, Cypress Bioscience, Cyberonics, Forest Laboratories, Medtronic, Organon, Neuronetics, Novartis, Pfizer, Solvay, Wyeth, Shire; he has received great support from Pfizer and Wyeth.

Figures

Fig. 1
Fig. 1
Baseline anxiety symptom severity levels and mean (s.e.) proportions of weeks in depressive episodes by follow-up period.
See this image and copyright information in PMC

Comment in

References

    1. Henry C, Van den Bulke D, Bellivier F, Etain B, Rouillon F, Leboyer M. Anxiety disorders in 318 bipolar patients: prevalence and impact on illness severity and response to mood stabilizer. J Clin Psychiatry 2003; 64: 331–5 - PubMed
    1. Fava M, Rush AJ, Alpert JE, Balasubramani GK, Wisniewski SR, Carmin CN, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry 2008; 165: 342–51 - PubMed
    1. Fava M, Uebelacker LA, Alpert JE, Nierenberg AA, Pava JA, Rosenbaum JF. Major depressive subtypes and treatment response. Biol Psychiatry 1997; 42: 568–76 - PubMed
    1. Feske U, Frank E, Kupfer DJ, Shear MK, Weaver E. Anxiety as a predictor of response to interpersonal psychotherapy for recurrent major depression: an exploratory investigation. Depress Anxiety 1998; 8: 135–41 - PubMed
    1. Feske U, Frank E, Mallinger AG, Houck PR, Fagiolini A, Shear MK, et al. Anxiety as a correlate of response to the acute treatment of bipolar I disorder. Am J Psychiatry 2000; 157: 956–62 - PubMed

Publication types

MeSH terms